What's in Mirum Pharmaceuticals's pipeline?

Mirum Pharmaceuticals has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Mirum Pharmaceuticals's portfolio?

Top competitors by shared drug class: , AbbVie.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mirum.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Mirum Pharmaceuticals — Portfolio Competitive Intelligence Brief

Mirum Pharmaceuticals (MIRM) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

MIRM (NASDAQ) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Cholbam	CHOLIC ACID	marketed	Bile Acid [EPC]	G-protein coupled bile acid receptor 1	Metabolic	2015-01-01

Therapeutic area mix

Metabolic · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mirum Pharmaceuticals:

Cite this brief

Drug Landscape (2026). Mirum Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mirum. Accessed 2026-05-14.